PE20020385A1 - Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada - Google Patents

Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada

Info

Publication number
PE20020385A1
PE20020385A1 PE2001000770A PE2001000770A PE20020385A1 PE 20020385 A1 PE20020385 A1 PE 20020385A1 PE 2001000770 A PE2001000770 A PE 2001000770A PE 2001000770 A PE2001000770 A PE 2001000770A PE 20020385 A1 PE20020385 A1 PE 20020385A1
Authority
PE
Peru
Prior art keywords
eletriptan
core
weight
composition
hours
Prior art date
Application number
PE2001000770A
Other languages
English (en)
Inventor
Raspide Manaud Pierre Frederic De
Mathias Walther
Ross James Macrae
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20020385A1 publication Critical patent/PE20020385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electroluminescent Light Sources (AREA)
  • Luminescent Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN NUCLEO DE ELETRIPTAN 3-{[1-METILPIRROLIDIN-2(R)-IL]METIL}-5-(2-FENILSULFONILETIL)1H-INDOL Y b) COADYUVANTES DE EXTRUSION, AGLUTINANTES, DILUYENTES. EL NUCLEO ESTA REVESTIDO CON UNO O MAS COPOLIMEROS ACRILICOS CON GRUPOS DE METACRILATO DE TRIMETILAMINOETILO. EL NUCLEO CONTIENEN HIDROBROMURO DE ELETRIPTAN, HEMISULFATO DE ELETRIPTAN CUYO DIAMETRO ES DE 0,2 mm A 2 mm Y CONTIENE DE 10% A 90% PESO/PESO DE ELETRIPTAN. SE REFIERE TAMBIEN A UNA COMPOSICION EN LA CUAL SE HA INSERTADO UNA CAPA PROTECTORA ADICIONAL ENTRE EL NUCLEO Y EL REVESTIMIENTO, PERMEABLE E INSOLUBLE EN AGUA SELECCIONADA DE HIDROXIPROPILMETILCELULOSA CON UN GROSOR DE 10 MICROMETROS A 100 MICROMETROS. LA COMPOSICION ES CAPAZ DE SUMINISTRAR ELETRIPTAN EN UNA SOLUCION TAMPONADA A pH 7,5 SIENDO DICHA COMPOSICION CAPAZ DE CONSEGUIR UN CURSO SIGMOIDEO DE LIBERACION CONTROLADA DEL FARMACO EN EL CUAL: a) 5% EN PESO DEL FARMACO HA SIDO LIBERADO EN UN PUNTO TEMPORAL DE 1,5 A 12 HORAS DESPUES DE LA ADICION; b) 50% EN PESO DEL FARMACO HA SIDO LIBERADO EN UN PUNTO TEMPORAL DE 5 A 15 HORAS DESPUES DE LA ADICON Y c) EL 80% EN PESO DEL FARMACO HA SIDO LIBERADO DE 6,5 A 20 HORAS DESPUES DE LA ADICION Y PROPORCIONA UNA CONCENTRACION PLASMATICA MEDIA DE ELETRIPTAN SUPERIOR A 10 ng/ml A LAS 20 HORAS DESPUES DE LA ADMINISTRACION. LA COMPOSICION ES AGONISTA DEL RECEPTOR 5-HT 1B/1D Y PUEDER SER USADA EN EL TRATAMIENTO DE MIGRANA
PE2001000770A 2000-08-02 2001-08-01 Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada PE20020385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition

Publications (1)

Publication Number Publication Date
PE20020385A1 true PE20020385A1 (es) 2002-05-11

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000770A PE20020385A1 (es) 2000-08-02 2001-08-01 Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada

Country Status (38)

Country Link
US (1) US20020034545A1 (es)
EP (1) EP1365748B1 (es)
JP (1) JP2004505034A (es)
KR (1) KR20030024820A (es)
CN (1) CN1630511A (es)
AP (1) AP2001002233A0 (es)
AR (1) AR030099A1 (es)
AT (1) ATE308978T1 (es)
AU (1) AU2001270932A1 (es)
BG (1) BG107361A (es)
BR (1) BR0112839A (es)
CA (1) CA2417887C (es)
CZ (1) CZ2003241A3 (es)
DE (1) DE60114887T2 (es)
EA (1) EA200300110A1 (es)
EC (1) ECSP034451A (es)
EE (1) EE200300051A (es)
ES (1) ES2250429T3 (es)
GB (1) GB0018968D0 (es)
GT (1) GT200100149A (es)
HR (1) HRP20030036A2 (es)
HU (1) HUP0301453A2 (es)
IL (1) IL153494A0 (es)
IS (1) IS6649A (es)
MA (1) MA26934A1 (es)
MX (1) MXPA03000999A (es)
NO (1) NO20030498D0 (es)
NZ (1) NZ522976A (es)
OA (1) OA12348A (es)
PA (1) PA8523101A1 (es)
PE (1) PE20020385A1 (es)
PL (1) PL359847A1 (es)
SK (1) SK1082003A3 (es)
SV (1) SV2002000574A (es)
TN (1) TNSN01115A1 (es)
UY (1) UY26861A1 (es)
WO (1) WO2002009675A1 (es)
ZA (1) ZA200300868B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US20060134012A1 (en) * 2002-12-16 2006-06-22 Symington John M Temporary pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
JP2006522790A (ja) * 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
ES2434416T3 (es) 2005-08-10 2013-12-16 Add Advanced Drug Delivery Technologies, Ltd. Preparación oral con liberación controlada
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
EP2359830B1 (en) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
US8137661B2 (en) 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
WO2011057676A1 (en) * 2009-11-16 2011-05-19 Evonik Röhm Gmbh A process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
FR3025425A1 (fr) * 2014-09-09 2016-03-11 Charleston Lab Inc Compositions pharmaceutiques
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
NZ522976A (en) 2004-11-26
UY26861A1 (es) 2002-02-28
HUP0301453A2 (hu) 2003-08-28
CA2417887C (en) 2006-11-14
DE60114887D1 (de) 2005-12-15
TNSN01115A1 (fr) 2005-11-10
EP1365748B1 (en) 2005-11-09
EP1365748A2 (en) 2003-12-03
SK1082003A3 (en) 2004-09-08
DE60114887T2 (de) 2006-07-20
CN1630511A (zh) 2005-06-22
PA8523101A1 (es) 2002-08-26
NO20030498L (no) 2003-01-31
AR030099A1 (es) 2003-08-13
WO2002009675A1 (en) 2002-02-07
MXPA03000999A (es) 2003-06-09
AP2001002233A0 (en) 2001-09-30
JP2004505034A (ja) 2004-02-19
CZ2003241A3 (cs) 2004-02-18
ES2250429T3 (es) 2006-04-16
EE200300051A (et) 2004-10-15
EA200300110A1 (ru) 2003-06-26
CA2417887A1 (en) 2002-02-07
BR0112839A (pt) 2003-06-24
ZA200300868B (en) 2004-04-16
IL153494A0 (en) 2003-07-06
WO2002009675A9 (en) 2003-07-10
PL359847A1 (en) 2004-09-06
NO20030498D0 (no) 2003-01-31
ATE308978T1 (de) 2005-11-15
US20020034545A1 (en) 2002-03-21
GT200100149A (es) 2002-06-25
BG107361A (bg) 2003-06-30
GB0018968D0 (en) 2000-09-20
SV2002000574A (es) 2002-12-02
MA26934A1 (fr) 2004-12-20
KR20030024820A (ko) 2003-03-26
AU2001270932A1 (en) 2002-02-13
OA12348A (en) 2004-03-19
ECSP034451A (es) 2003-03-10
HRP20030036A2 (en) 2003-04-30
IS6649A (is) 2002-12-05

Similar Documents

Publication Publication Date Title
PE20020385A1 (es) Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
RS50924B (sr) Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
RU2008117432A (ru) Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза
DE602005015686D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
UY30442A1 (es) Composiciones farmaccuticas de ropinirol, mctodos de uso, proceso de preparacinn y aplicaciones.
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
MA27523A1 (fr) Formulation retard a liberation controlee
PE20040130A1 (es) Composicion de tabletas de liberacion sostenida de pramipexol
DK1727551T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepinderivat og en inhibitor af RSV-fusionsproteinet
EA200701575A1 (ru) Формуляция леветирацетама длительного высвобождения
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
BRPI0410653A (pt) composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
HRP20100664T1 (hr) Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
GEP20125684B (en) Dipeptidyl peptidase inhibitors weekly administration
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
PE20070622A1 (es) Administracion de inhibidores de dipeptidil peptidasa
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
AR065077A1 (es) Composiciones farmaceuticas y metodos para utilizar temozolomida e inhibidores de quinasa multidirigidos

Legal Events

Date Code Title Description
FC Refusal